Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Spriggs

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Gynecologic Oncology|September 26, 2006
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyMargrit M Juretzka, Richard R Barakat, Dennis S Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumorsGary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-upRichard R Barakat, Paul Sabbatini, Dharmendra Bhaskaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumorsJakob Dupont, Bryan Bienvenu, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Gynecologic Oncology|October 24, 2007
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public WorkshopRobert C Bast, J Tate Thigpen, Susan G Arbuck, et al.
Gynecologic Oncology|October 7, 2006
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerCatherine S M Diefenbach, Zharna Shah, Alexia Iasonos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerPaul Sabbatini, Jakob Dupont, Carol Aghajanian, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Gynecologic Oncology|September 26, 2006
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyMargrit M Juretzka, Richard R Barakat, Dennis S Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumorsGary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-upRichard R Barakat, Paul Sabbatini, Dharmendra Bhaskaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumorsJakob Dupont, Bryan Bienvenu, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Gynecologic Oncology|October 24, 2007
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public WorkshopRobert C Bast, J Tate Thigpen, Susan G Arbuck, et al.
Gynecologic Oncology|October 7, 2006
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerCatherine S M Diefenbach, Zharna Shah, Alexia Iasonos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerPaul Sabbatini, Jakob Dupont, Carol Aghajanian, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Pageof 5